On the contrary, particular ccRCC driver genes do influence DDR and there is preclinical evidence to support the poly(ADP)-ribose polymerase (PARP) inhibition in VHL- or BAP1-mutated ccRCC [54,58,59]. This evidence concerns the gene BAP1 and nonpapillary renal cell carcinoma.